Ryan C A, Andrew M
Department of Pediatrics, University of Alberta Hospitals, Edmonton, Canada.
Am J Dis Child. 1992 Feb;146(2):187-93. doi: 10.1001/archpedi.1992.02160140053020.
In three children with central vein thromboses and a fourth with a pulmonary artery thrombosis, thrombolytic therapy failed to produce ultrasonographic evidence of clot lysis. Low-dose streptokinase (50 to 250 U/kg per hour) was infused directly into the clot in three children, followed by streptokinase and urokinase in systemic doses (streptokinase, 1000 to 1750 U/kg per hour; urokinase, 4400 to 5000 U/kg per hour). A fourth child treated sequentially with systemic doses of streptokinase, urokinase, and recombinant tissue-type plasminogen activator developed a significant retroperitoneal and intrapleural hemorrhage after 19 hours of recombinant tissue-type plasminogen activator infusion at a dose of 0.7 mg/kg per hour. All of the children survived. The most likely reason for treatment failure was that the clots (estimated to be between 2 and 3 weeks of age) were organized and thus resistant to lysis. Early diagnosis and prompt thrombolysis of significant lesions may contribute to the successful management of pediatric thrombosis. However, controlled studies are clearly needed to establish guidelines for the optimal use of thrombolytic agents in children.
在3例患有中心静脉血栓形成的儿童和另1例患有肺动脉血栓形成的儿童中,溶栓治疗未能产生血栓溶解的超声证据。对3例儿童直接向血栓内注入低剂量链激酶(每小时50至250 U/kg),随后给予全身剂量的链激酶和尿激酶(链激酶,每小时1000至1750 U/kg;尿激酶,每小时4400至5000 U/kg)。第4例儿童先后接受全身剂量的链激酶、尿激酶和重组组织型纤溶酶原激活剂治疗,在以每小时0.7 mg/kg的剂量输注重组组织型纤溶酶原激活剂19小时后发生了严重的腹膜后和胸腔内出血。所有儿童均存活。治疗失败的最可能原因是血栓(估计形成2至3周)已机化,因此对溶解有抵抗性。对明显病变进行早期诊断并迅速溶栓可能有助于成功处理儿童血栓形成。然而,显然需要进行对照研究以确立儿童溶栓药物最佳使用的指南。